Inocras, a biotechnology company specializing in whole-genome sequencing and genomic analysis, has secured $31 million through an oversubscribed Series B-3 financing round to accelerate the expansion of its cancer genomics platform in the United States.
The latest funding round brings Inocras’ total capital raised to approximately $100 million and includes participation from strategic investors, existing backers, and new financial partners. The investment will support the company’s efforts to strengthen its commercial infrastructure, expand clinical adoption, and advance the use of whole-genome analysis in cancer care.
The company’s technology focuses on using comprehensive genomic information to improve cancer profiling, treatment decisions, and disease monitoring. As precision medicine continues to reshape oncology, access to detailed genetic information and reliable biomarker analysis has become increasingly important for identifying treatment options, tracking disease progression, and supporting research initiatives.
Inocras aims to make whole-genome sequencing a more widely adopted tool in oncology by providing clinicians and researchers with broader insights compared with traditional targeted genetic testing approaches. The company believes its platform can help improve personalized treatment strategies while supporting areas such as clinical research and drug discovery.
The Series B-3 financing included investments from NDS Corporation, Aimed Bio Inc., DSC Investment, Dunamu & Partners, InterVest, Korea Investment & Securities, Shinhan Securities, Woori Investment & Securities, DT& Investment, IMM Investment, and LoftyRock Investment.
Whole-Genome Sequencing Platform Supports Cancer Profiling and Disease Monitoring
Founded in San Diego, Inocras develops genomic technologies designed to analyze the complete genetic landscape of tumors. Its primary platform, CancerVision, uses whole-genome sequencing to identify a wide range of genomic alterations associated with cancer.
Unlike conventional sequencing methods that examine limited genetic regions, whole-genome sequencing evaluates a broader set of genetic changes across the tumor profile. This approach allows researchers and healthcare providers to gain a more comprehensive understanding of tumor characteristics and identify clinically relevant genomic patterns.
CancerVision is designed to distinguish tumor-specific genetic alterations from inherited genetic sequences. The platform also provides genome-wide biomarker analysis, enabling researchers to examine potential indicators that may influence diagnosis, treatment selection, and disease monitoring.
The company’s second offering, MRDVision, builds on information generated through CancerVision. The test creates a personalized genomic baseline for each patient and tracks circulating tumor DNA (ctDNA) in blood samples over time.
Monitoring ctDNA can provide insights into residual disease following treatment by detecting small amounts of cancer-related genetic material that may remain in the body. By analyzing patient-specific genomic information across the entire genome rather than relying only on targeted gene panels, Inocras aims to provide a broader approach to monitoring cancer progression.
The company also works with healthcare providers, researchers, and patients by offering genomic testing services along with genetic counseling support. Through its platform, Inocras helps match eligible patients with clinical trials based on tumor characteristics, biomarkers, and other relevant criteria.
The growing interest in comprehensive genomic profiling reflects the changing landscape of cancer treatment. Pharmaceutical companies increasingly rely on genomic data to identify patient groups for clinical trials and develop therapies designed for specific molecular characteristics.
As drug discovery becomes more focused on targeted approaches, genomic platforms that provide detailed information about tumor biology are becoming valuable tools for researchers developing next-generation therapies.
Inocras Targets U.S. Expansion Following Clinical Adoption in Asia
Inocras plans to use the new funding to expand its presence in the U.S. market by building commercial operations, supporting healthcare partnerships, and increasing awareness of whole-genome sequencing applications in cancer care.
The company has already reported clinical adoption across Asia, where its technology has been used in thousands of patient cases. The experience gained through these deployments will serve as a foundation as Inocras works to expand its reach among U.S. hospitals, research institutions, and oncology networks.
Jehee Suh, CEO of Inocras, said the company’s next phase will focus on bringing its clinical experience and genomic capabilities to the U.S. healthcare market while supporting broader adoption of whole-genome analysis in cancer treatment.
The expansion comes as healthcare systems increasingly move toward precision oncology models that rely on deeper molecular understanding of individual tumors. Traditional cancer treatment approaches are gradually being complemented by genomic testing, allowing physicians to consider specific genetic characteristics when making treatment decisions.
Industry analysts note that demand for advanced cancer diagnostics continues to rise as oncology research becomes more data-driven. Comprehensive genomic profiling can support multiple stages of cancer management, including diagnosis, treatment selection, monitoring, and research.
However, broader adoption of whole-genome sequencing will depend on factors such as clinical validation, healthcare provider awareness, reimbursement pathways, and integration into routine oncology workflows.
Inocras’ latest financing provides resources to address these challenges while expanding its operational capabilities. The company plans to strengthen relationships with hospitals and clinicians while continuing to develop evidence supporting the clinical value of its genomic platforms.
With increasing investments in precision medicine and personalized cancer care, companies offering advanced sequencing technologies are positioned to play a significant role in the future of oncology. Inocras’ focus on whole-genome sequencing, personalized monitoring, and biomarker-driven insights reflects the industry’s ongoing shift toward more targeted and data-supported approaches to cancer management.
